US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others

As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.